Literature DB >> 29988228

Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management.

Monica Patten1, Simon Pecha2, Ali Aydin3.   

Abstract

Atrial fibrillation is common in hypertrophic cardiomyopathy with a prevalence of 22-32 %. The impact of atrial fibrillation on overall survival, left ventricular function, thromboembolic stroke and quality of life is crucial. This review enlightens incidence, pathophysiology, and clinical symptoms. Early recognition of atrial fibrillation is essential. Monitoring methods for early detection are described. Finally effective therapy options are discussed including oral anticoagulation and the role of interventional catheter-based ablation in the treatment of atrial fibrillation in HCM patients.

Entities:  

Keywords:  Atrial Fibrillation; Device Therapy; Epidemiology; Hypertrophic Cardiomyopathy; Implantable Cardioverter Defibrillator

Year:  2018        PMID： 29988228      PMCID： PMC6006972          DOI： 10.4022/jafib.1556

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN： 1941-6911


  62 in total

1.  A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).

Authors:  Constantinos O'Mahony; Fatima Jichi; Menelaos Pavlou; Lorenzo Monserrat; Aristides Anastasakis; Claudio Rapezzi; Elena Biagini; Juan Ramon Gimeno; Giuseppe Limongelli; William J McKenna; Rumana Z Omar; Perry M Elliott
Journal:  Eur Heart J       Date:  2013-10-14       Impact factor: 29.983

2.  Comparative effectiveness of catheter ablation strategies for rhythm control in patients with atrial fibrillation: a meta-analysis.

Authors:  Nazila Assasi; Feng Xie; Gord Blackhouse; Kathryn Gaebel; Diana Robertson; Rob Hopkins; Jeff S Healey; Ron Goeree
Journal:  J Interv Card Electrophysiol       Date:  2012-10-03       Impact factor: 1.900

3.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

4.  Catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy.

Authors:  Jordan M Prutkin; David S Owens
Journal:  Heart       Date:  2016-06-22       Impact factor: 5.994

5.  Exercise capacity and paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy.

Authors:  Farnaz Azarbal; Maneesh Singh; Gherardo Finocchiaro; Vy-Van Le; Ingela Schnittger; Paul Wang; Jonathan Myers; Euan Ashley; Marco Perez
Journal:  Heart       Date:  2013-12-10       Impact factor: 5.994

6.  Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.

Authors:  Raymond H Chan; Barry J Maron; Iacopo Olivotto; Michael J Pencina; Gabriele Egidy Assenza; Tammy Haas; John R Lesser; Christiane Gruner; Andrew M Crean; Harry Rakowski; James E Udelson; Ethan Rowin; Massimo Lombardi; Franco Cecchi; Benedetta Tomberli; Paolo Spirito; Francesco Formisano; Elena Biagini; Claudio Rapezzi; Carlo Nicola De Cecco; Camillo Autore; E Francis Cook; Susie N Hong; C Michael Gibson; Warren J Manning; Evan Appelbaum; Martin S Maron
Journal:  Circulation       Date:  2014-08-05       Impact factor: 29.690

7.  High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device.

Authors:  Iris Wilke; Katrin Witzel; Julia Münch; Simon Pecha; Stephan Blankenberg; Hermann Reichenspurner; Stephan Willems; Monica Patten; Ali Aydin
Journal:  J Cardiovasc Electrophysiol       Date:  2016-05-03

8.  Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy.

Authors:  T Jared Bunch; Thomas M Munger; Paul A Friedman; Samuel J Asirvatham; Peter A Brady; Yong-Mei Cha; Robert F Rea; Win-Kuang Shen; Brian D Powell; Steve R Ommen; Kristi H Monahan; Janis M Haroldson; Douglas L Packer
Journal:  J Cardiovasc Electrophysiol       Date:  2008-05-09

9.  Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy.

Authors:  Barry J Maron; Iacopo Olivotto; Pietro Bellone; Maria Rosa Conte; Franco Cecchi; Björn P Flygenring; Susan A Casey; Thomas E Gohman; Sergio Bongioanni; Paolo Spirito
Journal:  J Am Coll Cardiol       Date:  2002-01-16       Impact factor: 24.094

10.  Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA).

Authors:  Oliver P Guttmann; Menelaos Pavlou; Constantinos O'Mahony; Lorenzo Monserrat; Aristides Anastasakis; Claudio Rapezzi; Elena Biagini; Juan Ramon Gimeno; Giuseppe Limongelli; Pablo Garcia-Pavia; William J McKenna; Rumana Z Omar; Perry M Elliott
Journal:  Eur J Heart Fail       Date:  2015-07-16       Impact factor: 15.534
View more
  10 in total

Review 1.  Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment.

Authors:  George Makavos; Chris Κairis; Maria-Eirini Tselegkidi; Theodoros Karamitsos; Angelos G Rigopoulos; Michel Noutsias; Ignatios Ikonomidis
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

2.  Multimodality Imaging Demonstrating an Apical Variant Hypertrophic Cardiomyopathy in an Uncommon Pentad.

Authors:  Ayman R Fath; Clinton E Jokerst; Amro Aglan; Nawfal Mihyawi; Farouk Mookadam
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec

3.  Apical Hypertrophic Cardiomyopathy: The Variant Less Known.

Authors:  Rebecca K Hughes; Kristopher D Knott; James Malcolmson; João B Augusto; Saidi A Mohiddin; Peter Kellman; James C Moon; Gabriella Captur
Journal:  J Am Heart Assoc       Date:  2020-02-28       Impact factor: 5.501

4.  Utilization and Complications of Catheter Ablation for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy.

Authors:  Guy Rozen; Gabby Elbaz-Greener; Ibrahim Marai; Nizar Andria; Seyed Mohammadreza Hosseini; Yitschak Biton; E Kevin Heist; Jeremy N Ruskin; Yulia Gavrilov; Shemy Carasso; Diab Ghanim; Offer Amir
Journal:  J Am Heart Assoc       Date:  2020-06-23       Impact factor: 5.501

5.  Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study.

Authors:  Jung-Chi Hsu; Ya-Ting Huang; Lian-Yu Lin
Journal:  Aging (Albany NY)       Date:  2020-11-23       Impact factor: 5.682

Review 6.  Thromboembolism in Patients with Hypertrophic Cardiomyopathy.

Authors:  Lu Liu; Zheng Liu; Xiaoping Chen; Sen He
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

7.  Mendelian randomization as an approach to assess causal effects of inflammatory bowel disease on atrial fibrillation.

Authors:  LaiTe Chen; GuoSheng Fu; ChenYang Jiang
Journal:  Aging (Albany NY)       Date:  2021-04-06       Impact factor: 5.682

8.  Mendelian randomization study on atrial fibrillation and cardiovascular disease subtypes.

Authors:  Man Ki Kwok; Catherine Mary Schooling
Journal:  Sci Rep       Date:  2021-09-21       Impact factor: 4.379

9.  Male infant with Noonan syndrome with RAF-1 gene mutation who survived hypertrophic cardiomyopathy-induced fatal heart failure and uncontrollable arrhythmias.

Authors:  Mao Hagino; Chiharu Ota; Takehiko Onoki; Shinya Iwasawa
Journal:  BMJ Case Rep       Date:  2022-09-28

Review 10.  Hypertrophic Cardiomyopathy: An Overview of Genetics and Management.

Authors:  Polakit Teekakirikul; Wenjuan Zhu; Helen C Huang; Erik Fung
Journal:  Biomolecules       Date:  2019-12-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.